Savient gains on Krystexxa approval

Savient Pharmaceuticals Inc. (NASDAQ:SVNT) gained $5.22 (35%) to $19.98 on Wednesday after FDA approved Krystexxa pegloticase late Tuesday to treat chronic gout in adults refractory to conventional th...